CGC · Canopy Growth Corp
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Dec 20, 2023; bars on opposite sides are not compared.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CGC
this stock
Canopy Growth Corp
|
$420.92M | -14.5% | — | — | 5.9% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$66.37B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$58.66B | +16.9% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$47.69B | -1.4% | — | — | 0.0% |
|
HLN
Haleon plc
|
$44.35B | -0.4% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Dec 20, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CGC | -8.9% | +4.7% | -8.9% | -2.0% | -14.5% |
| SPY | -0.5% | -1.2% | +12.6% | -0.7% | +11.7% |
| vs SPY | -8.3% | +6.0% | -21.5% | -1.3% | -26.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.